Bristol-Myers Squibb Company holds the cleaner structural position, with the lead spread across valuation and profitability. Sanofi does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Bristol-Myers Squibb Company is in better shape — its trend is intact while Sanofi's trend has broken down. That puts structure and market broadly in agreement — Bristol-Myers Squibb Company's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (BMY: S&P 500, SAN.PA: STOXX 600).
This is not just a one-metric split: both valuation and profitability materially support the lead. The overall score gap is 23 points in favour of Bristol-Myers Squibb Company.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. BMY and SAN.PA share the same industry classification.
For a similarity-based comparison, see how BMY and Sanofi each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing and operating quality both support the lead here.
Left means cheaper relative valuation. Higher means stronger structure.
Bristol-Myers Squibb Company looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where BMY and SAN.PA each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a trailing P/E that is 9.2 turns lower.
Profitability gives the lead a second hard layer of support, with a 13.4-point operating margin advantage.
The lead is built on both valuation and profitability, making it broader than a single-dimension result.
Break down the BMY vs SAN.PA comparison across all dimensions with the full interactive tool.
Explore how BMY and SAN.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.